Cipla Eyes Generic Challenge To Sanofi-Synthelabo's Plavix

Law360, New York (July 26, 2004, 12:00 AM EDT) -- Indian generic drug maker Cipla is planning to apply for approval to sell its version of Sanofi-Synthelabo's Plavix, the blood-thinning drug already at the center of Sanofi’s drawn-out patent litigation against Canada's Apotex and India's Dr. Reddy's.

Sanofi has sued Apotex and Dr. Reddy’s for patent infringement over their plans for generic versions of Plavix in the U.S. District Court for the Southern District of New York in Manhattan.

"Dr Reddy and Apotex have already done it. We won't be the first to request this authorization,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.